MedPath

The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation

Phase 4
Conditions
Crohn's Disease
Ulcerative Colitis
Registration Number
NCT01078935
Lead Sponsor
The Baruch Padeh Medical Center, Poriya
Brief Summary

Fifty patients will get probiotics (109 bacteria \[L. acidophilus, B. bifidum, S. thermophilus, L. rhamnosus, L. casei\] in 2 capsules) and half will get placebo (2 capsules that look the same like the probiotic capsules and will contain microcrystalline cellulose, artificial brown color, magnesium strearate, and silica dioxide). The patients and the staff will be blinded to the identity of the study medications.

Each patient and volunteer will get the study medication for 6 weeks and will be evaluated twice - before enrollment and after 6 weeks of treatment. Routine clinical management will continue - with regular treatment as needed.

Each individual will be studied for changes in biochemical inflammatory and immunological markers and changes in flow medicated diameter that will be measured by the brachial artery method (that is evaluating endothelial function). Every patient will be evaluated for his/her ability to produce endothelial progenitor stem cells (EPCs).

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
100
Inclusion Criteria
  • patients with ulcerative colitis and crohns' disease
Exclusion Criteria

.

  • notable caveats are that arteries smaller than 2.5 mm

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Truelove and Witts Classification of Ulcerative Colitis2 years
Crohn's disease activity index (CDAI)2 years
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath